From Genome to Therapy: Integrating New Technologies with Drug Development (Record no. 12163)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 00646nam a2200181Ia 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 140223b2000 xxu||||| |||| 00| 0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9780471627449 |
| Terms of availability | 0.00 |
| 082 ## - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615.19 |
| Item number | FRO |
| 245 ## - TITLE STATEMENT | |
| Title | From Genome to Therapy: Integrating New Technologies with Drug Development |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) | |
| Place of publication, distribution, etc | New York |
| Name of publisher, distributor, etc | John Wiley & Sons, Inc. |
| Date of publication, distribution, etc | 2000 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 165p |
| 440 ## - SERIES STATEMENT/ADDED ENTRY--TITLE | |
| Title | Novartis Foundation Symposium |
| Volume number/sequential designation | 229 |
| 9 (RLIN) | 17529 |
| 600 ## - SUBJECT ADDED ENTRY--PERSONAL NAME | |
| Personal name | Drug Development |
| 9 (RLIN) | 372 |
| 600 ## - SUBJECT ADDED ENTRY--PERSONAL NAME | |
| Personal name | Genomes |
| 9 (RLIN) | 16748 |
| 710 ## - ADDED ENTRY--CORPORATE NAME | |
| Corporate name or jurisdiction name as entry element | Novartis Foundation |
| Relator term | Corporate Author |
| 9 (RLIN) | 17530 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Item type | Book |
| Call number prefix | 615.19 |
| Call number suffix | FRO |
| 995 ## - RECOMMENDATION 995 [LOCAL, UNIMARC FRANCE] | |
| Origin of item (home branch) (free text) | Pharmacy Lending |
| Genre | P00672 |
| Section | 615.19 |
| Recipient parent organisation code | P00672 |
No items available.